- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03 | 2 | Seeking Alpha | ||
| 18.03. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Gain Therapeutics reports biomarker data from Parkinson's trial | 1 | Investing.com | ||
| 18.03. | Gain Therapeutics legt vielversprechende Biomarker-Daten aus Parkinson-Studie vor | 18 | Investing.com Deutsch | ||
| 18.03. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 03.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 13 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data | 1 | Investing.com | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 3 | GlobeNewswire (USA) | ||
| 18.12.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease | 509 | GlobeNewswire (Europe) | Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever... ► Artikel lesen | |
| 03.12.25 | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.12.25 | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data | 12 | Investing.com | ||
| 28.11.25 | Gain Therapeutics reicht Prospektnachtrag für Aktienangebot über 35,5 Mio. USD ein | 2 | Investing.com Deutsch | ||
| 28.11.25 | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11.25 | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| 16.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAGE LABS | 13,830 | +0,29 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 0,136 | +10,19 % | Quince Therapeutics, Inc. - 10-K, Annual Report | ||
| FRACTYL HEALTH | 0,460 | -1,77 % | Fractyl Health, Inc.: Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in... ► Artikel lesen | |
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-1,63 %) liegt der Kurs bei 1,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.